Navigation Links
Novel mouse model for autism yields clues to a 50-year-old mystery
Date:3/20/2012

Early disruptions in serotonin signaling in the brain may contribute to autism spectrum disorder (ASD), and other "enduring effects on behavior," Vanderbilt University researchers report.

Serotonin is a brain chemical that carries signals across the synapse, or gap between nerve cells. The supply of serotonin is regulated by the serotonin transporter (SERT). In 2005, a team of Vanderbilt researchers led by Randy Blakely and James Sutcliffe identified rare genetic variations in children with ASD that disrupt SERT function.

In a new study published this week in the Proceedings of the National Academy of Sciences (PNAS), the researchers report the creation of a mouse model that expressed the most common of these variations.

The change is a very small one in biochemical terms, yet it appears to cause SERT in the brain to go into "overdrive" and restrict the availability of serotonin at synapses.

"The SERT protein in the brain of our mice appears to exhibit the exaggerated function and lack of regulation we saw using cell models," said Blakely, director of the Vanderbilt Silvio O. Conte Center for Neuroscience Research.

"Remarkably, these mice show changes in social behavior and communication from early life that may parallel aspects of ASD," noted first author Jeremy Veenstra-VanderWeele, assistant professor of Psychiatry, Pediatrics and Pharmacology.

The researchers conclude that a lack of serotonin during development may lead to long-standing changes in the way the brain is "wired."

In 1961, investigators at Yale discovered that as many as 30 percent of children with autism have elevated blood levels of serotonin, a finding described as "hyperserotonemia."

Since then, these findings have been replicated many times. Indeed, hyperserotonemia is the most consistently reported biochemical finding in autism, and is a highly inherited trait. Yet, the cause or significance of this "bio-marker" has remained shrouded in mystery.

Until now. In the current study, Veenstra-VanderWeele, Blakely and their colleagues showed that they could produce hyperserotonemia in mice that express a variant of a human SERT gene associated with autism.

Because the genetic change makes the transporter more active, higher levels of serotonin accumulate in platelets and therefore in the bloodstream. In the brain, overactive transporters should have the opposite effect lowering serotonin levels at the synapse and producing behavioral changes relevant to autism. That's exactly what the researchers observed.

Of course, no mouse model can completely explain or reproduce the human condition. Neither does a single genetic variation cause autism. Experts believe the wide spectrum of autistic behaviors represents a complex web of interactions between many genes and environmental factors.

But animal models are critical to exploring more deeply the basis for the developmental changes that are observed in ASD. The scientists are using these mice to explore how altered brain serotonin levels during development may produce long-lasting changes in behavior and impact the risk for autism.


'/>"/>

Contact: Bill Snyder
william.snyder@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert  

Related medicine news :

1. Unprecedented academic-industry collaboration seeks new drugs and novel treatments for autism
2. Novel plastics and textiles from waste with the use of microbes
3. UC San Diego among first in nation to treat brain cancer with novel viral vector
4. Students at Western University develop a novel way to teach interdisciplinary care
5. UH Case Medical Center publishes study on novel treatment for skin lymphoma
6. Mass. General researchers find novel way to prevent drug-induced liver injury
7. Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
8. NIH scientists identify novel approach to view inner workings of viruses
9. Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes
10. KalVista and JDRF form research partnership for novel treatment of diabetic eye disease
11. Novel brain tumor vaccine acts like bloodhound to locate cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel mouse model for autism yields clues to a 50-year-old mystery
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple ... picturesque Babcock Cove, recently received training and certification in Closed Pulse Irrigation™ ... a prestigious five-star rating from the Centers for Medicare and Medicaid Services, to have ...
(Date:8/22/2017)... ... ... “To Walk Away”: a captivating and romantic sequel to the romantic story ... is the creation of published author, Larry R. Sherman, a retired chemistry professor from ... religion, as well as four novels. , Though the book opens in 1947, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s ... and neglect, and the struggles faced while hoping for a better life. “Without ... author, Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents and ...
(Date:8/22/2017)... , ... August 22, 2017 , ... “Glimpses Of Light”: ... of the world. “Glimpses Of Light” is the creation of published author, J.M. Shepherd, ... in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is one ...
(Date:8/22/2017)... ... 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, ... stress of modern life continually makes more demands on time and energy, people are ... trap people in vicious high/low cycles and can also cause long term health issues. ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
Breaking Medicine Technology: